Anti-FAP recombinant antibody conjugated to a photoreactive dye, IR700, has been shown to discriminately eliminate FAP +ve CAFs in vitro in a dose-dependent manner − normal fibroblasts and OC cancer cells were unaffected with in vivo models having no observable side effects [141]. The gene discussed is FAP; the disease is cancer.